Hjem › Ikke-småcellet lungekreft › New York › Rochester
Kliniske studier for Ikke-småcellet lungekreft i Rochester, NY
13 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Rochester (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Rochester General Hospital, Rochester
- University of Rochester, Rochester
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekruttererFase 3
- Wilmot Cancer Institute ( Site 0141), Rochester
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekruttererFase 3
- Research Site, Rochester
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekruttererFase 3
- University of Rochester Medical Center, Rochester
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RekruttererFase 2/3
- Rochester General Hospital Infectious Disease, Rochester
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
RekruttererFase 3
- University of Rochester, Rochester
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Rochester, Rochester
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekruttererFase 3
- University of Rochester Medical Center, Rochester
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
RekruttererFase 1
- University of Rochester, Rochester
- University of Rochester, Rochester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- University of Rochester, Rochester
- Wilmot Cancer Institute at Webster, Webster · 10 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Rochester, Rochester
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
RekruttererFase 2
- University of Rochester, Rochester
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Rochester
- Akut myelogen leukemi16 studier
- Lungekreft15 studier
- Brystkreft15 studier
- Kreft (alle typer)14 studier
- Fedme14 studier
- Overvekt13 studier
- Prostatakreft10 studier
- Metastatisk kreft8 studier
- Multipelt myelom8 studier
- Blærekreft7 studier
- Myotonisk dystrofi7 studier
- Pankreaskreft7 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.